Peripheral and Central GLP-1 Receptor Populations Mediate the Anorectic Effects of Peripherally Administered GLP-1 Receptor Agonists, Liraglutide and Exendin-4
Open accessThe DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
Abstract
UNLABELLED: The long-acting glucagon-like peptide-1 receptor (GLP-1R) agonists, exendin-4 and liraglutide, suppress food intake and body weight. The mediating site(s) of action for the anorectic effects produced by peripheral administration of these GLP-1R agonists are not known. Experiments addressed whether food intake suppression after i.p. delivery of exendin-4 and liraglutide is mediated exclusively by peripheral GLP-1R or also involves direct central nervous system (CNS) GLP-1R activation. Results showed that CNS delivery [third intracerebroventricular (3(rd) ICV)] of the GLP-1R antagonist exendin-(9-39) (100 μg), attenuated the intake suppression by i.p. liraglutide (10 μg) and exendin-4 (3 μg), particularly at 6 h and 24 h. Control experiments show that these findings appear to be based neither on the GLP-1R antagonist acting as a nonspecific competing orexigenic signal nor on blockade of peripheral GLP-1R via efflux of exendin-(9-39) to the periphery. To assess the contribution of GLP-1R expressed on subdiaphragmatic vagal afferents to the anorectic effects of liraglutide and exendin-4, food intake was compared in rats with complete subdiaphragmatic vagal deafferentation and surgical controls after i.p. delivery of the agonists. Both liraglutide and exendin-4 suppressed food intake at 3 h, 6 h, and 24 h for controls; for subdiaphragmatic vagal deafferentation rats higher doses of the GLP-1R agonists were needed for significant food intake suppression, which was observed at 6 h and 24 h after liraglutide and at 24 h after exendin-4. CONCLUSION: Food intake suppression after peripheral administration of exendin-4 and liraglutide is mediated by activation of GLP-1R expressed on vagal afferents as well as direct CNS GLP-1R activation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This is consistent with some prior studies demonstrating a role for NTS GLP-1R neurons in physiological satiation/satiety and for some of the anorectic effects of various GLP-1RAs, with some reporting an absence of evidence of proxies for nausea (109‐113).”
From GLP-1 and the Neurobiology of Eating Control: Recent Advances (2025) · cites this paper as [110]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Physiology of Glucagon-like Peptide 1
Holst, J. J. (2007) · Physiological Reviews · doi:10.1152/physrev.00034.2006 · Cited by 3,371 · cited 2×
“The long-acting GLP-1R agonists, exendin-4 and liraglutide, are efficacious in the treatment of T2DM and may hold promise for the treatment of obesity (5, 6, 28).”
BackgroundOgden, C. L., Yanovski, S. Z., Carroll, M. D., & Flegal, K. M. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.052 · Cited by 1,561
Astrup, A., Rössner, S., Van Gaal, L., Rissanen, A., Niskanen, L., Al Hakim, M., Madsen, J., Rasmussen, M. F., & Lean, M. E. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61375-1 · Cited by 1,163
Abbott, C. R., Monteiro, M., Small, C. J., Sajedi, A., Smith, K. L., Parkinson, J. R. C., Ghatei, M. A., & Bloom, S. R. (2005) · Brain Research · doi:10.1016/j.brainres.2005.03.011 · Cited by 599 · cited 1×
“Similarly, others also show that ip administration of GLP-1 does not suppress short-term intake after total subdiaphragmatic vagotomy (12), and ip exendin-4 does not suppress intake up to 8 h after administration in capsaicintreated mice (50).”
BackgroundAgersø, H., Jensen, L. B., Elbrønd, B., Rolan, P., & Zdravkovic, M. (2002) · Diabetologia · doi:10.1007/s00125-001-0719-z · Cited by 510
Göke, R., Larsen, P. J., Mikkelsen, J. D., & Sheikh, S. P. (1995) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.1995.tb00650.x · Cited by 474
Vilsbøll, T., Zdravkovic, M., Le-Thi, T., Krarup, T., Schmitz, O., Courrèges, J.-P., Verhoeven, R., Bugánová, I., & Madsbad, S. (2007) · Diabetes Care · doi:10.2337/dc06-2593 · Cited by 468
Glucoreceptors Controlling Feeding and Blood Glucose: Location in the Hindbrain
Ritter, R. C., Slusser, P. G., & Stone, S. (1981) · Science · doi:10.1126/science.6264602 · Cited by 467 · cited 1×
“After a 7-d surgical recovery period, 3 ICV cannula placement was assessed by measurement of the sympathoadrenal-mediated hyperglycemic response to the cytoglucopenia induced by 5-thio-D-glucose (210 g in 2 l aCSF) (20).”
MethodGlucagon-like peptide-1 inhibits gastric emptying via vagal afferent-mediated central mechanisms
I˙meryüz, N., Yeğen, B. Ç., Bozkurt, A., Coşkun, T., Villanueva-Peñacarrillo, M. L., & Ulusoy, N. B. (1997) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.1997.273.4.g920 · Cited by 432
Blonde, L., Klein, E. J., Han, J., Zhang, B., Mac, S. M., Poon, T. H., Taylor, K. L., Trautmann, M. E., Kim, D. D., & Kendall, D. M. (2006) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2006.00602.x · Cited by 416
Cited by
Glucagon-like peptide 1 (GLP-1)
Müller, T. D., Finan, B., Bloom, S. R., D'Alessio, D., Drucker, D. J., Flatt, P. R., Fritsche, A., Gribble, F., Grill, H. J., Habener, J. F., et al. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.09.010 · Cited by 1,868
Self-citationAlhadeff, A. L., Rupprecht, L. E., & Hayes, M. R. (2012) · Endocrinology · doi:10.1210/en.2011-1443 · Cited by 515
Self-citationGLP-1 physiology informs the pharmacotherapy of obesity
Drucker, D. J. (2022) · Molecular Metabolism · doi:10.1016/j.molmet.2021.101351 · Cited by 510
Hindbrain Neurons as an Essential Hub in the Neuroanatomically Distributed Control of Energy Balance
Grill, H. J., & Hayes, M. R. (2012) · Cell Metabolism · doi:10.1016/j.cmet.2012.06.015 · Cited by 485
“At the same time, recent experiments show that the central nervous system (CNS) action of energy status signals such as leptin, ghrelin, glucagon-like peptide-1 (GLP-1), and peptide YY (PYY) affect food preference, the incentive value of food, and other cognitive controls of food intake (Batterham et al., 2007; Kanosk…”
BackgroundInfluentialSelf-citationNeuronal GLP1R mediates liraglutide’s anorectic but not glucose-lowering effect
Sisley, S., Gutierrez-Aguilar, R., Scott, M., D’Alessio, D. A., Sandoval, D. A., & Seeley, R. J. (2014) · Journal of Clinical Investigation · doi:10.1172/jci72434 · Cited by 397
“We and others have shown previously that CNS pharmacological blockade of the GLP1R increases food intake (19, 26) and that central GLP1Rs are important in the anorectic effects of peripheral liraglutide (5).”
Bettge, K., Kahle, M., Abd El Aziz, M. S., Meier, J. J., & Nauck, M. A. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12824 · Cited by 374
de la Monte, S. M. (2017) · Drugs · doi:10.1007/s40265-016-0674-0 · Cited by 331
GLP-1 and weight loss: unraveling the diverse neural circuitry
Kanoski, S. E., Hayes, M. R., & Skibicka, K. P. (2016) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00520.2015 · Cited by 290
Self-citationKanoski, S. E., Rupprecht, L. E., Fortin, S. M., De Jonghe, B. C., & Hayes, M. R. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.12.022 · Cited by 273
“…barrier (BBB) (Kastin and Akerstrom, 2003) and that food intake suppression by liraglutide and exendin-4 does not require vagal afferent signaling (Kanoski et al., 2011), our data suggest that part of the nausea response accompanying peripheral administration of longer-acting GLP-1R agonists is…”
InfluentialSelf-citationKnockdown of GLP-1 Receptors in Vagal Afferents Affects Normal Food Intake and Glycemia
Krieger, J.-P., Arnold, M., Pettersen, K. G., Lossel, P., Langhans, W., & Lee, S. J. (2016) · Diabetes · doi:10.2337/db15-0973 · Cited by 269
“Together, this strengthens the classical view that VAN GLP-1Rs mainly mediate shortterm satiation and may be one of several redundant eating control mechanisms comprising the gut-brain axis (7,9,16,33).”
BackgroundMethodSelf-citationCentral and peripheral GLP-1 systems independently suppress eating
Brierley, D. I., Holt, M. K., Singh, A., de Araujo, A., McDougle, M., Vergara, M., Afaghani, M. H., Lee, S. J., Scott, K., Maske, C., et al. (2021) · Nature Metabolism · doi:10.1038/s42255-021-00344-4 · Cited by 265
Parabrachial CGRP Neurons Control Meal Termination
Campos, C. A., Bowen, A. J., Schwartz, M. W., & Palmiter, R. D. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.04.006 · Cited by 262
“Many of these ‘‘satiety signals,’’ including the hormones cholecystokinin (CCK) and glucagon-like peptide 1 (GLP-1), act upon vagal sensory fibers that in turn synapse onto and activate caudal hindbrain neurons in the nucleus of the solitary tract (NTS) and area postrema (Abbott et al., 2005; Edwards et al., 1986; Kan…”
BackgroundGlucagon-Like Peptide 1 Receptors in Nucleus Accumbens Affect Food Intake
Dossat, A. M., Lilly, N., Kay, K., & Williams, D. L. (2011) · The Journal of Neuroscience · doi:10.1523/jneurosci.3262-11.2011 · Cited by 256
“A recent study suggests that the longer-term (i.e., 24 h) anorexic effects of peripheral injection of these agonists are in fact mediated by brain GLP-1Rs (Kanoski et al., 2011).”
GLP−1 receptor agonists for the treatment of obesity: Role as a promising approach
Wang, J.-Y., Wang, Q.-W., Yang, X.-Y., Yang, W., Li, D.-R., Jin, J.-Y., Zhang, H.-C., & Zhang, X.-F. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1085799 · Cited by 248
Seino, Y., & Yabe, D. (2013) · Journal of Diabetes Investigation · doi:10.1111/jdi.12065 · Cited by 247
Lockie, S. H., Heppner, K. M., Chaudhary, N., Chabenne, J. R., Morgan, D. A., Veyrat-Durebex, C., Ananthakrishnan, G., Rohner-Jeanrenaud, F., Drucker, D. J., DiMarchi, R., et al. (2012) · Diabetes · doi:10.2337/db11-1556 · Cited by 237
“Studies in animals have demonstrated that CNS–GLP-1R signaling contributes to the body weight–reducing effect of these agonists (3).”
BackgroundRegulation of energy balance by a gut–brain axis and involvement of the gut microbiota
Bauer, P. V., Hamr, S. C., & Duca, F. A. (2016) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-015-2083-z · Cited by 216
“However, it may be possible that the early satiating effects of these drugs mimic endogenous GLP-1, as subdiaphragmatic vagotomy attenuates short-term effects (but not long-term) on food intake, while CNS GLP-1R antagonism attenuates more long-term effects on food intake [83].”
BackgroundThe glucagon-like peptide 1 analogue Exendin-4 attenuates alcohol mediated behaviors in rodents
Egecioglu, E., Steensland, P., Fredriksson, I., Feltmann, K., Engel, J. A., & Jerlhag, E. (2013) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2012.11.009 · Cited by 207
“However, Ex4 readily crosses the bloodbrain barrier (Kastin and Akerstrom, 2003) and has anorexigenic properties independent of administration route (Kanoski et al., 2011).”
BackgroundGut vagal sensory signaling regulates hippocampus function through multi-order pathways
Suarez, A. N., Hsu, T. M., Liu, C. M., Noble, E. E., Cortella, A. M., Nakamoto, E. M., Hahn, J. D., de Lartigue, G., & Kanoski, S. E. (2018) · Nature Communications · doi:10.1038/s41467-018-04639-1 · Cited by 208
Self-citationThe endocrinology of food intake
Begg, D. P., & Woods, S. C. (2013) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2013.136 · Cited by 201
Heppner, K. M., Kirigiti, M., Secher, A., Paulsen, S. J., Buckingham, R., Pyke, C., Knudsen, L. B., Vrang, N., & Grove, K. L. (2015) · Endocrinology · doi:10.1210/en.2014-1675 · Cited by 196
Incretin hormones and the satiation signal
Holst, J. J. (2013) · International Journal of Obesity · doi:10.1038/ijo.2012.208 · Cited by 188
Obesity: Current and potential pharmacotherapeutics and targets
Narayanaswami, V., & Dwoskin, L. P. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.10.015 · Cited by 186
“A uthor M anuscript A uthor M anuscript A uthor M anuscript A uthor M anuscript (9–39) (100 μg/2 μl, ICV), attenuated the decrease in food intake induced by GLP-1 agonists, exendin-4 (3 μg/kg, IP) and liraglutide (10 μg/kg, IP) (Kanoski et al., 2011).”
Loss-of-function mutations in ADCY3 cause monogenic severe obesity
Saeed, S., Bonnefond, A., Tamanini, F., Mirza, M. U., Manzoor, J., Janjua, Q. M., Din, S. M., Gaitan, J., Milochau, A., Durand, E., et al. (2018) · Nature Genetics · doi:10.1038/s41588-017-0023-6 · Cited by 187
Hsu, T. M., Hahn, J. D., Konanur, V. R., Lam, A., & Kanoski, S. E. (2015) · Neuropsychopharmacology · doi:10.1038/npp.2014.175 · Cited by 176
“Recent findings show that HPFv neuronal processing regulates both anorectic and orexigenic aspects of feeding behavior via peripherally derived neuroendocrine signals (Kanoski et al, 2013, 2011b).”
BackgroundInfluentialSelf-citationSignalling from the periphery to the brain that regulates energy homeostasis
Kim, K.-S., Seeley, R. J., & Sandoval, D. A. (2018) · Nature Reviews Neuroscience · doi:10.1038/nrn.2018.8 · Cited by 183
Battle of GLP-1 delivery technologies
Yu, M., Benjamin, M. M., Srinivasan, S., Morin, E. E., Shishatskaya, E. I., Schwendeman, S. P., & Schwendeman, A. (2018) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.07.009 · Cited by 180
Mietlicki-Baase, E. G., Ortinski, P. I., Rupprecht, L. E., Olivos, D. R., Alhadeff, A. L., Pierce, R. C., & Hayes, M. R. (2013) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00413.2013 · Cited by 174
Self-citationGLP-1 receptor signaling is not required for reduced body weight after RYGB in rodents
Ye, J., Hao, Z., Mumphrey, M. B., Townsend, R. L., Patterson, L. M., Stylopoulos, N., Münzberg, H., Morrison, C. D., Drucker, D. J., & Berthoud, H.-R. (2014) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00491.2013 · Cited by 174
Glucagon-like Peptide-1 and the Central/Peripheral Nervous System: Crosstalk in Diabetes
Muscogiuri, G., DeFronzo, R. A., Gastaldelli, A., & Holst, J. J. (2017) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2016.10.001 · Cited by 171
The physiological control of eating: signals, neurons, and networks
Watts, A. G., Kanoski, S. E., Sanchez-Watts, G., & Langhans, W. (2022) · Physiological Reviews · doi:10.1152/physrev.00028.2020 · Cited by 168
Self-citationDissociable hindbrain GLP1R circuits for satiety and aversion
Huang, K.-P., Acosta, A. A., Ghidewon, M. Y., McKnight, A. D., Almeida, M. S., Nyema, N. T., Hanchak, N. D., Patel, N., Gbenou, Y. S. K., Adriaenssens, A. E., et al. (2024) · Nature · doi:10.1038/s41586-024-07685-6 · Cited by 166
Botfield, H. F., Uldall, M. S., Westgate, C. S. J., Mitchell, J. L., Hagen, S. M., Gonzalez, A. M., Hodson, D. J., Jensen, R. H., & Sinclair, A. J. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aan0972 · Cited by 163
“Previous studies have also demonstrated only moderate effects on attenuating exendin-4–induced food intake suppression at early time points after intracerebroventricular bolus of exendin 9-39 (47).”
Adams, J. M., Pei, H., Sandoval, D. A., Seeley, R. J., Chang, R. B., Liberles, S. D., & Olson, D. P. (2018) · Diabetes · doi:10.2337/db17-1385 · Cited by 159
“administration of glucagon-like peptide-1-(7-36) amide or exendin-(9-39) alters”
BackgroundInfluentialGLP-1 receptor agonist promotes brown remodelling in mouse white adipose tissue through SIRT1
Xu, F., Lin, B., Zheng, X., Chen, Z., Cao, H., Xu, H., Liang, H., & Weng, J. (2016) · Diabetologia · doi:10.1007/s00125-016-3896-5 · Cited by 157
Iepsen, E. W., Zhang, J., Thomsen, H. S., Hansen, E. L., Hollensted, M., Madsbad, S., Hansen, T., Holst, J. J., Holm, J.-C., & Torekov, S. S. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.05.008 · Cited by 156
Seufert, J., & Gallwitz, B. (2014) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12251 · Cited by 156
“Peripheral liraglutide or exendin-4 administration in male Sprague-Dawley rats has been shown to suppress food intake via vagal-dependent and -independent pathways that result in direct CNS GLP-1R activation [124].”
Backgroundvan Bloemendaal, L., Veltman, D. J., ten Kulve, J. S., Groot, P. F. C., Ruhé, H. G., Barkhof, F., Sloan, J. H., Diamant, M., & Ijzerman, R. G. (2015) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12506 · Cited by 151
Schmidt, H. D., Mietlicki-Baase, E. G., Ige, K. Y., Maurer, J. J., Reiner, D. J., Zimmer, D. J., Van Nest, D. S., Guercio, L. A., Wimmer, M. E., Olivos, D. R., et al. (2016) · Neuropsychopharmacology · doi:10.1038/npp.2015.362 · Cited by 148
“Activation of GLP-1 receptors produces a number of physiological responses including enhanced insulin secretion, inhibition of gastric emptying, and reduced food intake (Hayes et al, 2010; Holst, 2007; Kanoski et al, 2011; Lovshin and Drucker, 2009; Ruttimann et al, 2009).”
BackgroundSelf-citationThe role of glucagon‐like peptide‐1 impairment in obesity and potential therapeutic implications
Madsbad, S. (2014) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12119 · Cited by 146
“Further studies in rats have suggested that the suppression of food intake after peripheral administration of exendin-4 and liraglutide is mediated by combined activation of GLP-1 receptors on vagal afferents and in the CNS [53].”
BackgroundInfluentialThe intestine as an endocrine organ and the role of gut hormones in metabolic regulation
Bany Bakar, R., Reimann, F., & Gribble, F. M. (2023) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-023-00830-y · Cited by 144
Liraglutide and obesity: a review of the data so far
Ladenheim, E. (2015) · Drug Design, Development and Therapy · doi:10.2147/dddt.s58459 · Cited by 146
“56 The results from this study demonstrated that intraperitoneal administration of exendin (9-39) failed to block the effects of peripherally administered exendin-4 and liraglutide.”
Duarte, A. I., Candeias, E., Correia, S. C., Santos, R. X., Carvalho, C., Cardoso, S., Plácido, A. I., Santos, M. S., Oliveira, C. R., & Moreira, P. I. (2013) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2013.01.008 · Cited by 162
Sørensen, G., Reddy, I. A., Weikop, P., Graham, D. L., Stanwood, G. D., Wortwein, G., Galli, A., & Fink-Jensen, A. (2015) · Physiology & Behavior · doi:10.1016/j.physbeh.2015.06.013 · Cited by 140
The metabolic role of vagal afferent innervation
Waise, T. M. Z., Dranse, H. J., & Lam, T. K. T. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-018-0062-1 · Cited by 140
Astrocytes Regulate GLP-1 Receptor-Mediated Effects on Energy Balance
Reiner, D. J., Mietlicki-Baase, E. G., McGrath, L. E., Zimmer, D. J., Bence, K. K., Sousa, G. L., Konanur, V. R., Krawczyk, J., Burk, D. H., Kanoski, S. E., et al. (2016) · The Journal of Neuroscience · doi:10.1523/jneurosci.3579-15.2016 · Cited by 133
“This time point was selected based on previous research showing that the anorectic effects of central Ex-4 do not develop until 3 h postadministration (Hayes et al., 2011; Kanoski et al., 2011, 2012).”
BackgroundMethodSelf-citationShirazi, R., Palsdottir, V., Collander, J., Anesten, F., Vogel, H., Langlet, F., Jaschke, A., Schürmann, A., Prévot, V., Shao, R., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1306799110 · Cited by 137
“Two-way ANOVA revealed no interaction, and post hoc Tukey test after a one-way ANOVA [F (3,33) = 12.”
InfluentialBurmeister, M. A., Ayala, J. E., Smouse, H., Landivar-Rocha, A., Brown, J. D., Drucker, D. J., Stoffers, D. A., Sandoval, D. A., Seeley, R. J., & Ayala, J. E. (2017) · Diabetes · doi:10.2337/db16-1102 · Cited by 136
“(18) demonstrated that the anorectic effects of peripherally dosed Ex4 and liraglutide involve the activation of GLP-1R both on vagal afferents and in the CNS, whereas Secher et al.”
BackgroundAlhadeff, A. L., Baird, J.-P., Swick, J., Hayes, M. R., & Grill, H. J. (2014) · Neuropsychopharmacology · doi:10.1038/npp.2014.74 · Cited by 134
Self-citationFortin, S. M., Lipsky, R. K., Lhamo, R., Chen, J., Kim, E., Borner, T., Schmidt, H. D., & Hayes, M. R. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aay8071 · Cited by 127
“M. Tang-Christensen, P. J. Larsen, R. Göke, A. Fink-Jensen, D. S. Jessop, M. Møller, S. P. Sheikh, Central administration of GLP-1-(7-36) amide inhibits food and water intake in rats.”
BackgroundMethodInfluentialSelf-citationKabahizi, A., Wallace, B., Lieu, L., Chau, D., Dong, Y., Hwang, E., & Williams, K. W. (2022) · British Journal of Pharmacology · doi:10.1111/bph.15682 · Cited by 126
“GLP-1 acts through a G-protein–coupled receptor expressed on pancreatic beta cells and neurons of the central and peripheral nervous system (Kanoski et al., 2011; Nakagawa et al., 2004; Paternoster & Falasca, 2018; Sandoval et al., 2008; Vahl et al., 2007).”
BackgroundGLP-1 physiology in obesity and development of incretin-based drugs for chronic weight management
Holst, J. J. (2024) · Nature Metabolism · doi:10.1038/s42255-024-01113-9 · Cited by 125
“Aspects of these mechanisms were investigated by Kanoski et al. 111 .”
Hsu, T. M., Noble, E. E., Liu, C. M., Cortella, A. M., Konanur, V. R., Suarez, A. N., Reiner, D. J., Hahn, J. D., Hayes, M. R., & Kanoski, S. E. (2018) · Molecular Psychiatry · doi:10.1038/mp.2017.91 · Cited by 122
Self-citationMietlicki-Baase, E. G., Ortinski, P. I., Reiner, D. J., Sinon, C. G., McCutcheon, J. E., Pierce, R. C., Roitman, M. F., & Hayes, M. R. (2014) · The Journal of Neuroscience · doi:10.1523/jneurosci.0115-14.2014 · Cited by 121
“Nevertheless, several CNS nuclei send glutamatergic projections to the NAc core (Kelley et al., 2005), and the possibility that presynaptic GLP-1R in the core might regulate glutamatergic neurotransmission originating from additional or alternate (non-PFC) nuclei should not be discounted.”
BackgroundSelf-citationGLP-1 based therapeutics: simultaneously combating T2DM and obesity
Heppner, K. M., & Perez-Tilve, D. (2015) · Frontiers in Neuroscience · doi:10.3389/fnins.2015.00092 · Cited by 115
“Many treatments approved for T2DM treatment such as sulphonylureas and thiazolidinediones (TZDs) improve glucose metabolism but have the unwanted side effect of causing weight gain (Thule and Umpierrez, 2014) and (Kahn et al., 2006; Home et al., 2009; Ryan et al., 2011).”
BackgroundAgile delivery of protein therapeutics to CNS
Yi, X., Manickam, D. S., Brynskikh, A., & Kabanov, A. V. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.06.017 · Cited by 115
GLP-1 analog attenuates cocaine reward
Graham, D. L., Erreger, K., Galli, A., & Stanwood, G. D. (2013) · Molecular Psychiatry · doi:10.1038/mp.2012.141 · Cited by 114
Alhadeff, A. L., & Grill, H. J. (2014) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00179.2014 · Cited by 111
Self-citationThe modulatory role of high fat feeding on gastrointestinal signals in obesity
Duca, F. A., Sakar, Y., & Covașă, M. (2013) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2013.05.005 · Cited by 127
GLP-1 Influences Food and Drug Reward
Hayes, M. R., & Schmidt, H. D. (2016) · Current Opinion in Behavioral Sciences · doi:10.1016/j.cobeha.2016.02.005 · Cited by 108
Self-citationOng, Z. Y., Liu, J.-J., Pang, Z. P., & Grill, H. J. (2017) · Neuropsychopharmacology · doi:10.1038/npp.2017.150 · Cited by 112
“GLP-1 is a hormone with anorectic effects that are mediated in part through its receptors in the brain (Kanoski et al, 2011).”
Self-citationBilling, L. J., Larraufie, P., Lewis, J., Leiter, A., Li, J., Lam, B., Yeo, G. S., Goldspink, D. A., Kay, R. G., Gribble, F. M., et al. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.09.001 · Cited by 107
Fang, Y., Ji, L., Zhu, C., Xiao, Y., Zhang, J., Lu, J., Yin, J., & Wei, L. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.602574 · Cited by 108
“Murine primary hepatocytes were isolated from male C57BL/6J mice (8 weeks old) using the collagenase IV perfusion technique as previously described (Seglen, 1976; Klaunig et al., 1981).”
MethodSex and estrogens alter the action of glucagon-like peptide-1 on reward
Richard, J. E., Anderberg, R. H., López-Ferreras, L., Olandersson, K., & Skibicka, K. P. (2016) · Biology of Sex Differences · doi:10.1186/s13293-016-0059-9 · Cited by 102
Varin, E. M., Mulvihill, E. E., Baggio, L. L., Koehler, J. A., Cao, X., Seeley, R. J., & Drucker, D. J. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.05.055 · Cited by 104
Marty, V. N., Farokhnia, M., Munier, J. J., Mulpuri, Y., Leggio, L., & Spigelman, I. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.599646 · Cited by 102
Alhadeff, A. L., Mergler, B. D., Zimmer, D. J., Turner, C. A., Reiner, D. J., Schmidt, H. D., Grill, H. J., & Hayes, M. R. (2017) · Neuropsychopharmacology · doi:10.1038/npp.2016.246 · Cited by 102
“…expressed in both the periphery and central nervous system (CNS) are involved in mediating the metabolic effects of these exogenous GLP-1R agonists (Kanoski et al, 2011; Secher et al, 2014; Sisley et al, 2014) and thus it is important to understand the contributions of discrete GLP-1R populations…”
BackgroundSelf-citationA Role for GLP-1 in Treating Hyperphagia and Obesity
Grill, H. J. (2020) · Endocrinology · doi:10.1210/endocr/bqaa093 · Cited by 101
Self-citationLiraglutide for Type 2 diabetes and obesity: a 2015 update
Iepsen, E. W., Torekov, S. S., & Holst, J. J. (2015) · Expert Review of Cardiovascular Therapy · doi:10.1586/14779072.2015.1054810 · Cited by 101
Gastaldelli, A., Gaggini, M., Daniele, G., Ciociaro, D., Cersosimo, E., Tripathy, D., Triplitt, C., Fox, P., Musi, N., DeFronzo, R., et al. (2016) · Hepatology · doi:10.1002/hep.28827 · Cited by 96
“In addition to their effect on the pancreas, GLP-1 receptor agonists (GLP-1-RAs) can exert effects on tissues beyond the pancreas, including the liver and adipose tissue.((2-7)) In addition to their effect on glucose metabolism, evidence suggests that GLP-1-RAs also might influence lipid metabolism.”
BackgroundLoss of dorsomedial hypothalamic GLP-1 signaling reduces BAT thermogenesis and increases adiposity
Lee, S. J., Sanchez-Watts, G., Krieger, J.-P., Pignalosa, A., Norell, P. N., Cortella, A., Pettersen, K. G., Vrdoljak, D., Hayes, M. R., Kanoski, S. E., et al. (2018) · Molecular Metabolism · doi:10.1016/j.molmet.2018.03.008 · Cited by 95
Self-citationExendin-4 decreases amphetamine-induced locomotor activity
Erreger, K., Davis, A. R., Poe, A. M., Greig, N. H., Stanwood, G. D., & Galli, A. (2012) · Physiology & Behavior · doi:10.1016/j.physbeh.2012.03.014 · Cited by 95
“endin-4 decreases amphetam brain barrier [7–9].”
BackgroundKrieger, J.-P. (2020) · Peptides · doi:10.1016/j.peptides.2020.170342 · Cited by 91
The regulation of PKA signaling in obesity and in the maintenance of metabolic health
London, E., & Stratakis, C. A. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108113 · Cited by 104
Estradiol signaling in the regulation of reproduction and energy balance
Sinchak, K., & Wagner, E. J. (2012) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2012.08.004 · Cited by 109
“The ability of GLP-1 to attenuate energy intake is due to effects of the incretin on both the peripheral and central nervous systems (De Silva et al., 2011; Dossat et al., 2011; Kanoski et al., 2011; Washington et al., 2010).”
BackgroundDong, Y., Carty, J., Goldstein, N., He, Z., Hwang, E., Chau, D., Wallace, B., Kabahizi, A., Lieu, L., Peng, Y., et al. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2021.101352 · Cited by 93
Zhang, Y., Kahng, M. W., Elkind, J. A., Weir, V. R., Hernandez, N. S., Stein, L. M., & Schmidt, H. D. (2020) · Neuropsychopharmacology · doi:10.1038/s41386-019-0531-4 · Cited by 92
Reappraising the role of the vagus nerve in GLP-1-mediated regulation of eating
Brierley, D. I., & de Lartigue, G. (2022) · British Journal of Pharmacology · doi:10.1111/bph.15603 · Cited by 92
“…or vagotomy abolish peripheral GLP-1 induced satiation (Abbott et al., 2005; Talsania et al., 2005; Hayes, Kanoski, de Jonghe, et al., 2011; Kanoski et al., 2011; Labouesse et al., 2012), glucose tolerance (Abbott et al., 2005; I˙meryüz et al., 1997) and inhibition of gastric emptying…”
BackgroundHayes, M. R., Mietlicki-Baase, E. G., Kanoski, S. E., & De Jonghe, B. C. (2014) · Annual Review of Nutrition · doi:10.1146/annurev-nutr-071812-161201 · Cited by 92
“When systemically administered, the GLP-1R agonists liraglutide and exendin-4 sufficiently penetrate the blood-brain barrier (BBB) and gain access to the brain in amounts sufficient to drive a physiological/behavioral response (80, 83), making it difficult to disentangle the effects originating in the periphery from t…”
Self-citationFortin, S. M., & Roitman, M. F. (2017) · Physiology & Behavior · doi:10.1016/j.physbeh.2017.03.019 · Cited by 90
Self-citationDissecting the Physiology and Pathophysiology of Glucagon-Like Peptide-1
Paternoster, S., & Falasca, M. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00584 · Cited by 91
Dong, M., Wen, S., & Zhou, L. (2022) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s375559 · Cited by 90
Inoue, K., Maeda, N., Kashine, S., Fujishima, Y., Kozawa, J., Hiuge-Shimizu, A., Okita, K., Imagawa, A., Funahashi, T., & Shimomura, I. (2011) · Cardiovascular Diabetology · doi:10.1186/1475-2840-10-109 · Cited by 89
“Recent experiments show that the anorectic effect of peripheral GLP-1 administration is mediated both by the activation of GLP-1 receptor (GLP-1R) expressed on vagal afferents and by the GLP-1R activation in central nervous system [13].”
Perspectives in GLP-1 Research: New Targets, New Receptors
Cantini, G., Mannucci, E., & Luconi, M. (2016) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2016.03.017 · Cited by 102
“Experiments performed in rat models suggested that these effects are in part mediated by activation of afferent neuronal GLP-1R, expressed on vagal afferents, and in part by CNS expressed GLP-1R [33].”
BackgroundCandeias, E., Sebastião, I., Cardoso, S., Carvalho, C., Santos, M. S., Oliveira, C. R., Moreira, P. I., & Duarte, A. I. (2017) · Molecular Neurobiology · doi:10.1007/s12035-017-0622-3 · Cited by 94
Suarez, A. N., Liu, C. M., Cortella, A. M., Noble, E. E., & Kanoski, S. E. (2020) · Biological Psychiatry · doi:10.1016/j.biopsych.2019.10.012 · Cited by 88
“Exendin-4 at this dose are dependent on vagal afferent signaling (45).”
BackgroundSelf-citationHayes, M. R., Kanoski, S. E., De Jonghe, B. C., Leichner, T. M., Alhadeff, A. L., Fortin, S. M., Arnold, M., Langhans, W., & Grill, H. J. (2011) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00356.2011 · Cited by 86
Self-citationGhrelin Signaling Affects Feeding Behavior, Metabolism, and Memory through the Vagus Nerve
Davis, E. A., Wald, H. S., Suarez, A. N., Zubcevic, J., Liu, C. M., Cortella, A. M., Kamitakahara, A. K., Polson, J. W., Arnold, M., Grill, H. J., et al. (2020) · Current Biology · doi:10.1016/j.cub.2020.08.069 · Cited by 84
Self-citationPabreja, K., Mohd, M. A., Koole, C., Wootten, D., & Furness, S. G. B. (2014) · British Journal of Pharmacology · doi:10.1111/bph.12313 · Cited by 84
“…humans, GLP-1 enhances satiety (Tang-Christensen et al., 1996; Turton et al., 1996; Flint et al., 1998; Näslund et al., 1998; Williams et al., 2009; Kanoski et al., 2011; Renner et al., 2012) and inhibition of gastric emptying (Imeryüz et al., 1997; Näslund et al., 1998; Delgado-Aros et al., 2002;…”
BackgroundGut-brain connection: The neuroprotective effects of the anti-diabetic drug liraglutide
Candeias, E. M. (2015) · World Journal of Diabetes · doi:10.4239/wjd.v6.i6.807 · Cited by 83
GLP-1 and Its Analogs: Does Sex Matter?
Börchers, S., & Skibicka, K. P. (2025) · Endocrinology · doi:10.1210/endocr/bqae165 · Cited by 77
Nucleus accumbens GLP-1 receptors influence meal size and palatability
Dossat, A. M., Diaz, R., Gallo, L., Panagos, A., Kay, K., & Williams, D. L. (2013) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00137.2013 · Cited by 80
“However, agonists such as exenatide and liraglutide can cross the blood-brain barrier, and at least some portion of their effects on food intake is mediated through stimulation of central GLP-1R (15).”
BackgroundThe importance of estradiol for body weight regulation in women
Vigil, P., Meléndez, J., Petkovic, G., & Río, J. P. D. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.951186 · Cited by 98
Costa, A., Ai, M., Nunn, N., Culotta, I., Hunter, J., Boudjadja, M. B., Valencia-Torres, L., Aviello, G., Hodson, D. J., Snider, B. M., et al. (2022) · Molecular Metabolism · doi:10.1016/j.molmet.2021.101407 · Cited by 79
McKay, N. J., Kanoski, S. E., Hayes, M. R., & Daniels, D. (2011) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00472.2011 · Cited by 79
“Nevertheless, the hypodipsic effect of GLP-1 agonists after central administration was clear, suggesting that at least part of the effect was mediated by central substrates, similar to studies done on food intake (16).”
ResultSelf-citationMcKinley, M. J., Denton, D. A., Ryan, P. J., Yao, S. T., Stefanidis, A., & Oldfield, B. J. (2019) · Journal of Neuroendocrinology · doi:10.1111/jne.12689 · Cited by 78
Sirohi, S., Schurdak, J. D., Seeley, R. J., Benoit, S. C., & Davis, J. F. (2016) · Physiology & Behavior · doi:10.1016/j.physbeh.2016.04.013 · Cited by 76
Regulation of body weight: Lessons learned from bariatric surgery
Albaugh, V. L., He, Y., Münzberg, H., Morrison, C. D., Yu, S., & Berthoud, H. (2022) · Molecular Metabolism · doi:10.1016/j.molmet.2022.101517 · Cited by 83
Zhao, S., Kanoski, S. E., Yan, J., Grill, H. J., & Hayes, M. R. (2012) · International Journal of Obesity · doi:10.1038/ijo.2011.265 · Cited by 76
Self-citationNeural integration of satiation and food reward: Role of GLP-1 and orexin pathways
Williams, D. L. (2014) · Physiology & Behavior · doi:10.1016/j.physbeh.2014.03.013 · Cited by 74
Metadata
- Authors
- Kanoski, S. E., Fortin, S. M., Arnold, M., Grill, H. J., & Hayes, M. R.
- Affiliations
- University of Pennsylvania (US)
- ETH Zurich (CH)
- Corresponding author
- Kanoski, Scott E.
- Venue
- Endocrinology
- Publisher
- The Endocrine Society
- Published
- 2011-06-21
- Volume
- 152
- Issue
- 8
- Pages
- 3103-3112
- ISSN
- 0013-7227 (ISSN-L)
- 1945-7170
- PMC
- PMC3138234
- OpenAlex
- W1965072462
- Cited by
- 347
- References
- 51
- Citations by year
- 2026: 16 · 2025: 26 · 2024: 21 · 2023: 16 · 2022: 18 · 2021: 30 · 2020: 23 · 2019: 26 · 2018: 19 · 2017: 21 · 2016: 27 · 2015: 24 · 2014: 22 · 2013: 25 · 2012: 23
- FWCI
- 11.85
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Endocrinology (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- University of Pennsylvania
- National Institutes of Health (DK21397, DK089752)
- National Institute of Diabetes and Digestive and Kidney Diseases (DK089752, DK085435, R01DK021397, F32DK089752, K01DK085435, DK 21397, R56DK021397)
- Topics
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Keywords
- GLP-1 receptor agonists, liraglutide, exendin-4, exendin-9-39, feeding inhibition, anorectic effect, vagal afferents, intracerebroventricular administration, appetite regulation
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Liraglutide, Exenatide, Animals, Appetite Depressants, Body Weight, Brain, Calcitonin, Eating, Male, Peptide Fragments, Peptides, Vagus Nerve, Venoms, Rats, Sprague-Dawley, Receptors, Glucagon, Rats, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.